Citable company snapshot
Alnylam Pharmaceuticals's latest SEC-sourced 2026-06-30 period shows $1.29B in revenue and $164.49M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $1.29B | $1.17B | +10.6% |
| Operating Income | Jun 30, 2026 | $231.44M | $268.64M | -13.8% |
| Net Income | Jun 30, 2026 | $164.49M | $205.99M | -20.1% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $326.72M | $70.50M | +363.4% |
| Free Cash Flow (computed) | Jun 30, 2026 | $292.04M | $48.67M | +500.0% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Jul 30, 2026; accession 0001178670-26-000062.
ALNY company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.